Warfarin-treated patients had a significantly lower level of carboxylated osteocalcin [31], while carboxylated osteocalcin was potentially protective against diabetes and reported to be associated with reduced insulin resistance [32, 33], fasting glucose [33], and odds of metabolic syndrome [34] in human. Here, BGLAP is linked to diabetes mellitus.